FINWIRES · TerminalLIVE
FINWIRES

SHE:000739

9 stories mentioning SHE:000739Updated 2d ago

Every FINWIRES story that references SHE:000739, newest first.

Asia

Apeloa Pharmaceutical Unit Wins China Approval for Levocarnitine Oral Solution; Shares Up 5%

Apeloa Pharmaceutical's (SHE:000739) unit Zhejiang Apeloa Kangyu Pharmaceutical received a drug registration certificate from China's National Medical Products Administration for its levocarnitine oral solution, according to a Shenzhen bourse filing on Wednesday.The drug is used to treat primary systemic carnitine deficiency and secondary carnitine deficiency.The pharmaceutical company's shares jumped 5% during the afternoon trade.

SHE:000739
Asia

Apeloa Pharmaceutical Unit Signs Cooperation Agreement With Two Biotech Firms; Shares Down 3%

Apeloa Pharmaceutical's (SHE:000739) subsidiary, Zhejiang Ante Yutai Biotechnology, entered into a cooperation agreement with Shanghai Wuxi Biologics and Shanghai Duoning Biotechnology, according to a Shenzhen bourse filing on Tuesday.Under the deal, Wuxi Biologics will provide research, development and manufacturing services to Ante Yutai.Duoning Biotech will also provide key consumables and supporting hardware to Ante Yutai for biologics research and development, and manufacturing.The pharmaceutical company's shares fell 3% during the afternoon trade.

SHE:000739
Asia

Apeloa Pharmaceutical Obtains EU Certificate for Gabapentin; Shares Down 2%

Apeloa Pharmaceutical (SHE:000739) obtained a certificate of suitability from the European Union for the gabapentin active pharmaceutical ingredient, according to a Shenzhen bourse filing on Thursday.The drug is used for the treatment of postherpetic neuralgia in adults and epilepsy in children.The pharmaceutical company's shares fell nearly 2% during the afternoon trade.

SHE:000739
Asia

Apeloa Pharmaceutical to Set Up 10 Million Yuan Joint Venture

Apeloa Pharmaceutical (SHE:000739) plans to establish a joint venture with three other investors, according to a Shenzhen bourse filing on Friday.The venture, Zhejiang Ante Yutai Biotechnology, will manufacture antibody and protein drugs, and other biopharmaceutical products and will have a registered capital of 10 million yuan.The company will own 34.6% of the venture.The pharmaceutical company's shares slumped 6% at the close.

SHE:000739
Asia

Apeloa Pharmaceutical's Unit Gets EU Certificate for Amantadine Hydrochloride

Apeloa Pharmaceutical's (SHE:000739) unit, Zhejiang Apeloa Kangyu Pharmaceutical, received a certificate of suitability from the European Union for its amantadine hydrochloride, according to a Shenzhen bourse filing on Friday.The drug is used to treat symptoms caused by influenza A virus infection, as well as Parkinson's Disease.

SHE:000739
Asia

Apeloa Pharmaceutical Gets US FDA Nod for Hypertension, Angina Treatment

The U.S. Food and Drug Administration approved Apeloa Pharmaceutical's (SHE:000739) metoprolol succinate extended-release tablets, according to a Friday disclosure to the Shenzhen bourse.The drug is indicated for hypertension and angina pectoris or chest pain, as well as symptomatic stable chronic heart failure with dysfunction in the left ventricle, among others.

SHE:000739
Asia

Apeloa Pharmaceutical Subsidiary Gets China Approval for Antibiotic

China's drug regulator approved the cefpodoxime proxetil raw material produced by Apeloa Pharmaceutical (SHE:000739) Zhejiang subsidiary, according to a Saturday filing with the Shenzhen bourse.The ingredient is an antibiotic, suited for upper and lower respiratory tract infections, uncomplicated urinary tract infections, and other bacterial infections, the filing said.

SHE:000739
Asia

Apeloa Pharmaceutical Q1 Profit Inches Up; Shares Rise 4%

Apeloa Pharmaceutical (SHE:000739) posted first-quarter attributable net profit of 249.0 million yuan, up 0.2% from 248.5 million yuan the previous year.Earnings per share rose to 0.2152 yuan from 0.2126 yuan, according to a Tuesday filing with the Shenzhen bourse.Operating revenue declined 10% year over year to 2.45 billion yuan from 2.73 billion yuan.Shares of the pharmaceutical company were up 4% in recent trade.

SHE:000739
Asia

Apeloa Pharmaceutical Gets China Nod for Cholesterol-Lowering Drug

China's drug regulator approved Apeloa Pharmaceutical's (SHE:000739) registration for its fluvastatin sodium extended-release tablets, according to a Thursday filing with the Shenzhen bourse.Fluvastatin sodium is indicated for cholesterol lowering, the filing said.

SHE:000739

Track with the FINWIRES app suite

FolioX
FolioX
Track SHE:000739 in your portfolio
WheelAI
WheelAI
Analyze SHE:000739 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SHE:000739